ReviewJournal of innate immunity2016
What Really Rigs Up RIG-I?
Review in Journal of innate immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- AI-Assisted Computed Structure Models for Pre-Ubiquitylation Complexes Assembled by Respiratory Syncytial Viral Suppressors of Cellular Interferon Response.International journal of molecular sciences · 2026Article
- Exposure of negative-sense viral RNA in the cytoplasm initiates innate immunity to West Nile virus.Molecular cell · 2025Article
- Intestinal-pulmonary axis: a 'Force For Good' against respiratory viral infections.Frontiers in immunology · 2025Review
- Identification of shared gene signatures and biological mechanisms between preeclampsia and polycystic ovary syndrome.Heliyon · 2024Article
- Modifying the antiviral innate immune response by selective writing, erasing, and reading of mCell chemical biology · 2024Review
- Suppression of Innate Immunity by the Hepatitis C Virus (HCV): Revisiting the Specificity of Host-Virus Interactive Pathways.International journal of molecular sciences · 2023Review
- Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity.Cancer immunology, immunotherapy : CII · 2023Article
- How RNA modifications regulate the antiviral response.Immunological reviews · 2021Review
- Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease.Neuropsychiatric disease and treatment · 2021Review
- Blocking tombusvirus replication through the antiviral functions of DDX17-like RH30 DEAD-box helicase.PLoS pathogens · 2019Article
- Journal of Innate Immunity Ten Years Later.Journal of innate immunity · 2018Article
- The nonstructural proteins of Pneumoviruses are remarkably distinct in substrate diversity and specificity.Virology journal · 2017Article
- Fighting Cancer with Mathematics and Viruses.Viruses · 2017Review
- Article
- Current concepts in maternal-fetal immunology: Recognition and response to microbial pathogens by decidual stromal cells.American journal of reproductive immunology (New York, N.Y. : 1989) · 2017Review
- Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?Frontiers in immunology · 2017Review
- Identification of Interferon-Stimulated Gene Proteins That Inhibit Human Parainfluenza Virus Type 3.Journal of virology · 2016Article
- On PAMPs and DAMPs.Journal of innate immunity · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RIG-I (retinoic acid-inducible gene 1) is an archetypal member of the cytoplasmic DEAD-box dsRNA helicase family (RIG-I-like receptors or RLRs), the members of which play essential roles in the innate immune response of the metazoan cell. RIG-I functions as a pattern recognition receptor that detects nonself RNA as a pathogen-associated molecular pattern (PAMP). However, the exact molecular nature of the viral RNAs that act as a RIG-I ligand has remained a mystery and a matter of debate. In this article, we offer a critical review of the actual viral RNAs that act as PAMPs to activate RIG-I, as seen from the perspective of a virologist, including a recent report that the viral Leader-read-through transcript is a novel and effective RIG-I ligand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.